Skip to Main Content

Author Details

Martin S Tallman
Memorial Sloan-Kettering Cancer Center
1982
652
115
PMIDPaper TitleJournal TitlePublished Year
37824808Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune monitoring from the E1912 trial.Blood2024
36251406Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia.Am J Hematol2023
38066899How to avoid early mortality in acute promyelocytic leukemia.Hematology Am Soc Hematol Educ Program2023
37611216What Influences the Decision to Proceed to Transplant for Patients With AML in First Remission?J Clin Oncol2023
37688521Prospective analysis to determine barriers to allogeneic hematopoietic cell transplantation in patients with acute leukemia.Am J Hematol2023
37185873Obesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: An ECOG-ACRIN analysis.Cancer2023
37142255Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia.Blood Adv2023
37267439Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis.Blood Adv2023
37131653Acute myeloid leukemia stratifies as two clinically relevant sphingolipidomic subtypes.bioRxiv2023
36399715North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need.Blood2023
36580665DNA polymerase θ protects leukemia cells from metabolically induced DNA damage.Blood2023
36269846The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study.Blood Adv2023
36263593Clinical significance of mitochondrial DNA content in acute promyelocytic leukaemia.Br J Haematol2023
34316017Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results.Leukemia2022
35349669Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia.Blood Adv2022
35838753Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia.Blood Adv2022
35767897International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.Blood2022
35797463Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.Blood2022
35427411Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.Blood2022
35598475De Novo myelodysplastic syndromes in patients 20-50 years old are enriched for adverse risk features.Leuk Res2022
35487785Harnessing the power of sphingolipids: Prospects for acute myeloid leukemia.Blood Rev2022
36509740Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia.Blood Cancer J2022
36070610Development of a distributed international patient data registry for hairy cell leukemia.Leuk Lymphoma2022
36332294Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling.Leuk Res2022
35930750Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy.Blood2022
35922444Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.Leukemia2022
36151075Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999.Blood Cancer J2022
33539850Liposomal cytarabine and daunorubicin (CPX-351/Vyxeos)-associated distinct purpuric subtype of toxic erythema of chemotherapy: A retrospective review of 54 patients.J Am Acad Dermatol2022
35043475Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia at first relapse.Eur J Haematol2022
34981142Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.Ann Hematol2022
34854276A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia.Haematologica2022
35178674Advances in the Treatment of Hairy Cell Leukemia Variant.Curr Treat Options Oncol2022
34674293Multicenter evaluation of efficacy and toxicity of venetoclax-based combinations in patients with accelerated and blast phase myeloproliferative neoplasms.Am J Hematol2022
34551064Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML.Blood Adv2022
34711640Intracellular Cholesterol Pools Regulate Oncogenic Signaling and Epigenetic Circuitries in Early T-cell Precursor Acute Lymphoblastic Leukemia.Cancer Discov2022
32868875Interferon alpha therapy in essential thrombocythemia and polycythemia vera-a systematic review and meta-analysis.Leukemia2021
33687434Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML.Blood Adv2021
33654204Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial.Leukemia2021
33650111The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapy.Am J Hematol2021
33541192Incorporation of Novel therapies for the treatment of acute myeloid leukemia: a perspective.Leuk Lymphoma2021
33785862Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR.Leukemia2021
33895809Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL.Blood2021
33857746Arsenic trioxide therapy predisposes to herpes zoster reactivation despite minimally myelosuppressive therapy.Leuk Res2021
33496745Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia.Blood Adv2021
34587866Does the conventional cytogenetic risk profile still matter for prediction of venetoclax based treatment outcomes in AML?Leuk Lymphoma2021
34407545Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.Blood2021
34551341Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation-A Systematic Review and Meta-Analysis.Transplant Cell Ther2021
34519611Measurable residual disease negativity in acute myeloid leukemia: the destination may matter more than the journey.Leuk Lymphoma2021
34687602Harnessing the benefits of available targeted therapies in acute myeloid leukaemia.Lancet Haematol2021
34597373CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trials.Blood Adv2021
  • 1 - 50 of 652

Recommended Authors

Maria Amaya
University of Colorado School of Medicine
Career Start Year 2018
Number of shared co-authors 1
Curtis A Lachowiez
University of Texas MD Anderson Cancer Center
Career Start Year 2017
Number of shared co-authors 12
Jessica Leonard
Oregon Health & Science University
Career Start Year 2015
Number of shared co-authors 17
Hein Than
Singapore General Hospital
Career Start Year 2012
Number of shared co-authors 11
Jennifer N Saultz
Knight Cancer Institute, Oregon Health and Science University
Career Start Year 2012
Number of shared co-authors 11
Friedrich St??lzel
University Hospital TU Dresden
Career Start Year 2008
Number of shared co-authors 14
Jennifer Dunlap
Oregon Health & Science University
Career Start Year 2008
Number of shared co-authors 12
Thomas K??hnke
Cancer Institute, Stanford University School of Medicine
Career Start Year 2008
Number of shared co-authors 1
Amanda Winters
University of Colorado School of Medicine
Career Start Year 2008
Number of shared co-authors 1
Felicitas Thol
Hannover Medical School
Career Start Year 2007
Number of shared co-authors 20
Paulo Vidal Campregher
Hospital Israelita Albert Einstein
Career Start Year 2007
Number of shared co-authors 3
Thomas Cluzeau
Universite Nice Cote d'azur, CHU de Nice
Career Start Year 2005
Number of shared co-authors 14
Tara L Lin
University of Kansas Medical Center
Career Start Year 2004
Number of shared co-authors 20
Jean-Baptiste Micol
INSERM U7, Universite Paris-Saclay
Career Start Year 2004
Number of shared co-authors 26
Patrick Brown
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Career Start Year 2004
Number of shared co-authors 28
Christopher R Cogle
College of Medicine, University of Florida
Career Start Year 2003
Number of shared co-authors 22
Vivian G Oehler
Fred Hutchinson Cancer Center.
Career Start Year 2003
Number of shared co-authors 19
Eneida R Nemecek
Oregon Health Sciences University
Career Start Year 2002
Number of shared co-authors 7
Thomas Ernst
Universitatsklinikum Jena
Career Start Year 2002
Number of shared co-authors 9
Ravindra Majeti
Stanford University School of Medicine
Career Start Year 1998
Number of shared co-authors 15
Wendy Hu
The University of Texas MD Anderson Cancer Center
Career Start Year 1995
Number of shared co-authors 4
Timothy S Pardee
Comprehensive Cancer Center of Wake Forest Baptist Health, Medical Center Boulevard
Career Start Year 1995
Number of shared co-authors 9
Thoralf Lange
Hospital Weissenfels
Career Start Year 1994
Number of shared co-authors 13
Michael W Becker
James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester
Career Start Year 1992
Number of shared co-authors 9
Claude Gardin
Avicenne Hospital
Career Start Year 1990
Number of shared co-authors 6
Claude Preudhomme
Lille University Hospital, INSERM UMR-S7, CNRS UMR9020, Lille University.
Career Start Year 1989
Number of shared co-authors 22
Clayton A Smith
University of Colorado, Aurora CO.
Career Start Year 1987
Number of shared co-authors 6
Alan S Wayne
Cancer and Blood Disease Institute, Children's Hospital Los Angeles
Career Start Year 1986
Number of shared co-authors 14
Ulrich D??hrsen
University Hospital Essen, University of Duisburg-Essen
Career Start Year 1979
Number of shared co-authors 8
Wolfgang E Berdel
University Hospital Munster
Career Start Year 1976
Number of shared co-authors 19

Collaborators

Richard M Stone
Dana Farber Cancer Institute
Co-authored papers 52
Hagop Kantarjian
The University of Texas MD Anderson Cancer Center
Co-authored papers 32
Farhad Ravandi
University of Texas M.D. Anderson Cancer Center
Co-authored papers 24
Ari Melnick
Co-authored papers 23
Andrew M Evens
Rutgers Robert Wood Johnson Medical School
Co-authored papers 22
Charles L Bennett
University of South Carolina
Co-authored papers 22
Steven M Trifilio
Northwestern Memorial Hospital
Co-authored papers 16
Donna Neuberg
Co-authored papers 16
Timothy M Kuzel
548377Rush University Medical Center
Co-authored papers 16
David A Rizzieri
Duke University Medical Center
Co-authored papers 14
Jerald P Radich
Fred Hutchinson Cancer Center
Co-authored papers 14
Jorge Cortes
Georgia Cancer Center
Co-authored papers 13
Daniel A Pollyea
University of Colorado Division of Hematology
Co-authored papers 12
Courtney D DiNardo
UT MD Anderson Cancer Center
Co-authored papers 12
June M McKoy
Feinberg School of Medicine, Northwestern University
Co-authored papers 12
Daniel J DeAngelo
Dana-Farber Cancer Institute
Co-authored papers 12
Charles G Mullighan
St Jude Children's Research Hospital
Co-authored papers 11
Antonella Sassano
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Co-authored papers 11
John F DiPersio
Washington University School of Medicine
Co-authored papers 10
John T Schiller
David Geffen School of Medicine at university of california los angeles
Co-authored papers 10
Dennis W Raisch
The University of New Mexico
Co-authored papers 10
Francine E Garrett-Bakelman
University of Virginia
Co-authored papers 10
Dietger Niederwieser
University of Leipzig
Co-authored papers 9
Mithat Gonen
Co-authored papers 9
Bruno C Medeiros
AbbVie Inc.
Co-authored papers 9
Krzysztof Mr??zek
The Ohio State Comprehensive Cancer Center
Co-authored papers 9
Anthony V Moorman
Translational and Clinical Research Institute, Newcastle University
Co-authored papers 9
Richard T Maziarz
Oregon Health & Science University
Co-authored papers 9
Mignon L Loh
University of Washington
Co-authored papers 8
Justin M Watts
University of Miami, Sylvester Comprehensive Cancer Center
Co-authored papers 8
Release 1.2